Journal
MABS
Volume 4, Issue 6, Pages 761-774Publisher
LANDES BIOSCIENCE
DOI: 10.4161/mabs.22276
Keywords
etanercept; biosimilar; TNF receptor 2-Fc fusion protein; N-Glycosylation; sialic acid; intact mass; MS/MS; charge variant; CE-LIF
Categories
Funding
- National Natural Science Foundation of China
- Ministry of Science and Technology of China (973 and 863 program projects)
- State Key Project for New Drug Development [2012ZX09304008, 2010ZX09401-407]
- Ministry of Education (Key Laboratory)
- Shanghai Commission of Science and Technology (Key Laboratory and Projects)
- Shanghai Leading Academic Discipline Project [B905]
Ask authors/readers for more resources
Because of rapidly increasing market demand and rising cost pressure, the innovator of etanercept (Enbrel (R)) will inevitably face competition from biosimilar versions of the product. In this study, to elucidate the differences between the reference etanercept and its biosimilars, we characterized and compared the quality attributes of two commercially available, biosimilar TNF receptor 2-Fc fusion protein products. Biosimilar 1 showed high similarity to Enbrel (R) in critical quality attributes including peptide mapping, intact mass, charge variant, purity, glycosylation and bioactivity. In contrast, the intact mass and MS/MS analysis of biosimilar 2 revealed a mass difference indicative of a two amino acid residue variance in the heavy chain (Fc) sequences. Comprehensive glycosylation profiling confirmed that biosimilar 2 has significantly low sialylated N-oligosaccharides. Biosimilar 2 also displayed significant differences in charge attributes compared with the reference product. Interestingly, biosimilar 2 exhibited similar affinity and bioactivity levels compared with the reference product despite the obvious difference in primary structure and partial physiochemical properties. For a biosimilar development program, comparative analytical data can influence decisions about the type and amount of animal and clinical data needed to demonstrate biosimilarity. Because of the limited clinical experience with biosimilars at the time of their approval, a thorough knowledge surrounding biosimilars and a case-by-case approach are needed to ensure the appropriate use of these products.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available